Bull of the Day: Globus Medical (GMED)

Globus Medical beat Q1 EPS by 22% at $1.12 versus $0.92 consensus, while revenue rose 27% year over year to $759.9 million versus $730 million expected. Management raised full-year non-GAAP EPS guidance to $4.70-$4.80 from $4.40-$4.50 and analysts have lifted current-year EPS estimates from $3.89 to $4.66 over 90 days. The offset is continued Nevro restructuring pressure, which kept revenue guidance flat, but the core spine franchise and margins remain strong.

Analysis

GMED’s setup is better than a simple post-earnings beat: the market is being handed evidence that margin expansion is now endogenous to the business, not just a function of mix or timing. That matters because in med-tech, sustained estimate revisions usually come from operating leverage plus channel trust, and once both are present, the multiple tends to re-rate before the next top-line inflection shows up. The fastest second-order winner is the neurology/spine ecosystem around GMED: higher procedure adoption pulls through consumables, instruments, and service attach, which tends to pressure smaller spine players and independent distributors that lack a robotics or implant breadth story.

The most important near-term tell is whether the Nevro drag remains isolated rather than infecting the consolidated growth narrative. If the base spine franchise keeps comping at roughly double-digit rates while the acquired asset stabilizes, GMED can absorb the restructuring over the next 2-3 quarters and still post upward EPS revisions, which is usually when the stock stops trading like a cyclical and starts trading like a quality compounder. A failure mode is that management keeps using the acquisition as a reason to cap revenue guidance, which can delay multiple expansion even if earnings keep beating.

From a risk standpoint, the stock’s recent support at the 200-day/61.8% retracement looks technically constructive, but that also creates a clean line in the sand: if it loses the low-$75 area again, the market is likely signaling doubt that the earnings inflection is durable. The bigger macro risk is a delayed hospital capital spending cycle or procedure normalization after the current share gains, but the estimate revision velocity suggests sell-side models are still under-embedding the margin slope over the next 6-12 months.

Consensus appears to be underpricing how much the installed-base model can compound once the robot stack is used to lock in recurring consumable pull-through. The market is treating Nevro as a headline drag, but the more relevant question is whether GMED has crossed the threshold where core growth can self-fund integration noise. If yes, the current pullback is more likely a reset in timing than a reset in terminal value.

Key Decisions for Investors

• Initiate a tactical long GMED on dips into the $75-$79 zone over the next 1-2 weeks; target a retrace toward the low/mid-$90s as the market re-prices the revised EPS runway, with risk defined on a weekly close below $74.
• For higher-conviction exposure, buy GMED Jan-2026 $85 or $90 calls on weakness; the asymmetry is attractive if the stock reclaims the 50-day and multiple expands on continued estimate revisions, but time decay is acceptable only if the Nevro drag normalizes by mid-year.
• Pair trade: long GMED / short a lower-quality spine or device laggard with weaker revision momentum over the next quarter; the thesis is that capital will continue rotating into names with accelerating margins and upward consensus, while legacy names without robotics/consumables leverage underperform.
• Use any failure to reclaim the 50-day moving average in the next 2-3 weeks as a de-risk trigger; if GMED cannot regain momentum after a major beat, the market is likely flagging that guidance conservatism is masking integration issues.